pharmaphorum Podcast
pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for those who want insight into the future of health and medicine.
Listen on:
Episodes
Friday Feb 26, 2021
Friday Feb 26, 2021
For episode 30 I spoke with Dr Ashton Harper, who’s head of medical affairs in the UK and Ireland at Roche Diagnostics, about the pressure COVID-19 has put on healthcare systems.
A former NHS doctor, he noted how stressful and draining some days can be when working at healthcare’s frontline - even in normal times, and that the current fight against the pandemic brings little respite to staff.
Friday Feb 12, 2021
Friday Feb 12, 2021
In this episode of the pharmaphorum podcast, our news editor Richard Staines talks to Richard Francis, who took over as CEO of gene therapy company Purespring Therapeutics earlier this month.
Francis was previously CEO of Sandoz, Novartis’ generics and biosimilars division, where he led the development of biosimilars and also sat on the Swiss pharma company’s executive committee.
Friday Jan 29, 2021
Friday Jan 29, 2021
The theme for episode 28 of the pharmaphorum podcast is diversity and inclusion in pharma, ably addressed by AstraZeneca’s Rebekah Martin.
Serving as senior vice president of reward and inclusion at AstraZeneca, Rebekah discussed how the pharmaceutical industry approaches the promotion of diversity.
In an episode that was recorded in December 2020, she also talked about what inclusion and diversity mean to her company.
Tuesday Jan 05, 2021
Tuesday Jan 05, 2021
Episode two of the Alderley Park Discovery Podcast covers access to skills in the life sciences sector, with a focus on support for aspiring scientists and UK staffing trends.
In this instalment Dominic Tyer’s guests on the podcast are Sai Life Sciences’ head of global R&D Dean Edney, Joynes & Hunt’s managing director Steve Joynes and Dr Kath Mackay, managing director at Bruntwood SciTech’s Alderley Park.
Monday Dec 21, 2020
Monday Dec 21, 2020
In episode 27 of the pharmaphorum podcast I’m joined by Erin McEachren, who’s EU Regional Vice President at J&J Surgical Vision.
She talks about her priorities at J&J, having joined the company six months ago, the current state of the medical devices sector and some of the trends she’s keeping a close eye on.
Monday Nov 30, 2020
Monday Nov 30, 2020
In episode 26 the pharmaphorum podcast hears from David Solomon, a 30-year life sciences industry veteran who recently took up the position of CEO at the Paris-based biopharmaceutical company Pharnext.
Friday Oct 30, 2020
Friday Oct 30, 2020
GlaxoSmithKline’s Nucala (mepolizumab) last month became the first and only biologic treatment approved in the US for Hypereosinophilic Syndrome (HES).
It’s part of the company’s focus on eosinophil-driven diseases and ahead of that regulatory milestone I spoke with Tiffany Robinson-Smith, who’s global medical affairs lead for biologics at GSK, about eosinophils and why they’re an important element of her company’s research programmes.
Monday Sep 28, 2020
Monday Sep 28, 2020
In this episode of the podcast Gitte discusses telemedicine, GN Hearing’s work in this area – and the impact of COVID-19, plus her time at LEO Pharma.
Tuesday Sep 15, 2020
Tuesday Sep 15, 2020
The Alderley Park Discovery Podcast, produced in partnership with pharmaphorum, presents perspectives on UK and global bioscience innovation trends, with input from key experts including managing director and leader of Bruntwood SciTech’s Alderley Park Dr Kath Mackay.
Thursday Aug 27, 2020
Thursday Aug 27, 2020
Anlnylam’s Brendan Martin joined the pharmaphorum podcast for episode 23 to talk about his company’s work in gene-silencing and how it could offer a route to target the current coronavirus pandemic.